hVIVO plc (AIM:HVO)
London · Delayed Price · Currency is GBP · Price in GBX 8.13
-0.12 (-1.45%)
Jun 16, 2026, 9:05 AM GMT
hVIVO Revenue
In the year 2025, hVIVO had annual revenue of 49.66M GBP, down -25.00%. hVIVO had revenue of 24.22M in the half year ending December 31, 2025, a decrease of -19.33%.
Revenue
49.66M
Revenue Growth
-25.00%
P/S Ratio
1.14
Revenue / Employee
132.07K
Employees
301
Market Cap
56.68M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 49.66M | -16.56M | -25.00% |
| Dec 31, 2024 | 66.22M | 7.55M | 12.87% |
| Dec 31, 2023 | 58.67M | 7.97M | 15.72% |
| Dec 31, 2022 | 50.70M | 11.69M | 29.98% |
| Dec 31, 2021 | 39.01M | 17.06M | 77.76% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bioventix | 12.54M |
| IXICO | 7.28M |
| SkinBioTherapeutics | 5.23M |
| Arecor Therapeutics | 1.71M |
| 4basebio | 1.69M |
| Ondine Biomedical | 1.43M |
| Faron Pharmaceuticals Oy | 1.14M |
| ImmuPharma | -69.96K |
hVIVO News
- 14 days ago - Decoy Therapeutics Partners With HVIVO To Advance D-MAV Into Clinical Study; Stock Up - Nasdaq
- 2 months ago - Full Year 2025 hVIVO PLC Earnings Presentation Transcript - GuruFocus
- 2 months ago - hVIVO Earnings Call Transcript: H2 2025 - Transcripts
- 2 months ago - hVIVO Annual report: H2 2025 - Filings
- 2 months ago - hVIVO Slides: H2 2025 - Filings
- 2 months ago - hVIVO Annual report: H2 2025 - Filings
- 4 months ago - hVIVO Earnings Call Transcript: Q4 2025 - Transcripts
- 4 months ago - hVIVO Earnings release: Q4 2025 - Filings